|
Mar 11
|
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
|
|
Mar 11
|
The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)
|
|
Mar 10
|
Zacks Investment Ideas feature highlights: Gilead Sciences and Johnson & Johnson
|
|
Mar 10
|
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
|
|
Feb 23
|
Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks
|
|
Feb 21
|
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP
|
|
Feb 21
|
Some Investors May Be Willing To Look Past Gilead Sciences' (NASDAQ:GILD) Soft Earnings
|
|
Feb 20
|
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
|
|
Feb 20
|
GILD or VRTX: Which Is the Better Value Stock Right Now?
|
|
Feb 20
|
Gilead Sciences, Inc. (GILD): Among Stocks That Analysts Think Will Go Up
|
|
Feb 20
|
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
|
|
Feb 20
|
High Growth Tech Stocks in the United States to Watch
|
|
Feb 20
|
How To Trade Stocks: Do You Know The Seven Most Important Words On Wall Street?
|
|
Feb 19
|
Gilead Sciences to Present at Upcoming Investor Conferences
|
|
Feb 19
|
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News
|
|
Feb 18
|
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use
|
|
Feb 18
|
Gilead Sciences Full Year 2024 Earnings: Beats Expectations
|
|
Feb 18
|
Deutsche Bank upgrades Gilead on its HIV treatment franchise
|
|
Feb 18
|
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
|
|
Feb 17
|
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
|